• Picture of Prof. Michael Sela

    Prof. Michael Sela

    Share Email
    An aptamer strategy to target oncogenic signaling in ErbB2 carrying human tumors.
    Collaboration with:  G. Mahlknecht , Y. Yarden G. Mahlknecht
    Synergy of antibodies towards decreasing pancreatic cancer.
    Collaboration with:  R. Maron, B. Schechter, Y. Yarden
    Towards vaccination: Generation of peptide mimotopes specific for anti ErbB-2 monoclonal antibodies.
    Collaboration with:  E. Witsch, Y. Yarden
    Mechanism of action of Copolymer 1 (Copaxone), a therapeutic vaccine against multiple sclerosis.
    Collaboration with:  R. Arnon
    Effective synergism by anti ErbB-2 mAb combinations comprising one mAb against the dimerization site of ErbB-2.
    Collaboration with:  Y. Yarden
    Monoclonal antibodies (mAbs) to ErbB-1 and ErbB-2 receptors and their role in potential anti-tumor strategy.
    Collaboration with:  B. Schechter, Y. Yarden
    Synergistic effects of combinations of mAb against distinct epitopes on EGFR/ErbB-1 and ErbB-2 receptors: accelerated receptor aggregation, down regulation and inhibition of tumor growth.
    Collaboration with:  B. Schechter, Y. Yarden
  • Picture of Prof. Michael Sela

    Prof. Michael Sela

    Share Email
    An aptamer strategy to target oncogenic signaling in ErbB2 carrying human tumors.
    Collaboration with:  G. Mahlknecht , Y. Yarden G. Mahlknecht
    Synergy of antibodies towards decreasing pancreatic cancer.
    Collaboration with:  R. Maron, B. Schechter, Y. Yarden
    Towards vaccination: Generation of peptide mimotopes specific for anti ErbB-2 monoclonal antibodies.
    Collaboration with:  E. Witsch, Y. Yarden
    Mechanism of action of Copolymer 1 (Copaxone), a therapeutic vaccine against multiple sclerosis.
    Collaboration with:  R. Arnon
    Effective synergism by anti ErbB-2 mAb combinations comprising one mAb against the dimerization site of ErbB-2.
    Collaboration with:  Y. Yarden
    Monoclonal antibodies (mAbs) to ErbB-1 and ErbB-2 receptors and their role in potential anti-tumor strategy.
    Collaboration with:  B. Schechter, Y. Yarden
    Synergistic effects of combinations of mAb against distinct epitopes on EGFR/ErbB-1 and ErbB-2 receptors: accelerated receptor aggregation, down regulation and inhibition of tumor growth.
    Collaboration with:  B. Schechter, Y. Yarden
  • Picture of Prof. Michael Sela

    Prof. Michael Sela

    Share Email
    An aptamer strategy to target oncogenic signaling in ErbB2 carrying human tumors.
    Collaboration with:  G. Mahlknecht , Y. Yarden G. Mahlknecht
    Synergy of antibodies towards decreasing pancreatic cancer.
    Collaboration with:  R. Maron, B. Schechter, Y. Yarden
    Towards vaccination: Generation of peptide mimotopes specific for anti ErbB-2 monoclonal antibodies.
    Collaboration with:  E. Witsch, Y. Yarden
    Mechanism of action of Copolymer 1 (Copaxone), a therapeutic vaccine against multiple sclerosis.
    Collaboration with:  R. Arnon
    Effective synergism by anti ErbB-2 mAb combinations comprising one mAb against the dimerization site of ErbB-2.
    Collaboration with:  Y. Yarden
    Monoclonal antibodies (mAbs) to ErbB-1 and ErbB-2 receptors and their role in potential anti-tumor strategy.
    Collaboration with:  B. Schechter, Y. Yarden
    Synergistic effects of combinations of mAb against distinct epitopes on EGFR/ErbB-1 and ErbB-2 receptors: accelerated receptor aggregation, down regulation and inhibition of tumor growth.
    Collaboration with:  B. Schechter, Y. Yarden
  • Picture of Prof. Michael Sela

    Prof. Michael Sela

    Share Email
    An aptamer strategy to target oncogenic signaling in ErbB2 carrying human tumors.
    Collaboration with:  G. Mahlknecht , Y. Yarden G. Mahlknecht
    Synergy of antibodies towards decreasing pancreatic cancer.
    Collaboration with:  R. Maron, B. Schechter, Y. Yarden
    Towards vaccination: Generation of peptide mimotopes specific for anti ErbB-2 monoclonal antibodies.
    Collaboration with:  E. Witsch, Y. Yarden
    Mechanism of action of Copolymer 1 (Copaxone), a therapeutic vaccine against multiple sclerosis.
    Collaboration with:  R. Arnon
    Effective synergism by anti ErbB-2 mAb combinations comprising one mAb against the dimerization site of ErbB-2.
    Collaboration with:  Y. Yarden
    Monoclonal antibodies (mAbs) to ErbB-1 and ErbB-2 receptors and their role in potential anti-tumor strategy.
    Collaboration with:  B. Schechter, Y. Yarden
    Synergistic effects of combinations of mAb against distinct epitopes on EGFR/ErbB-1 and ErbB-2 receptors: accelerated receptor aggregation, down regulation and inhibition of tumor growth.
    Collaboration with:  B. Schechter, Y. Yarden
  • Picture of Prof. Michael Sela

    Prof. Michael Sela

    Share Email
    An aptamer strategy to target oncogenic signaling in ErbB2 carrying human tumors.
    Collaboration with:  G. Mahlknecht , Y. Yarden G. Mahlknecht
    Synergy of antibodies towards decreasing pancreatic cancer.
    Collaboration with:  R. Maron, B. Schechter, Y. Yarden
    Towards vaccination: Generation of peptide mimotopes specific for anti ErbB-2 monoclonal antibodies.
    Collaboration with:  E. Witsch, Y. Yarden
    Mechanism of action of Copolymer 1 (Copaxone), a therapeutic vaccine against multiple sclerosis.
    Collaboration with:  R. Arnon
    Effective synergism by anti ErbB-2 mAb combinations comprising one mAb against the dimerization site of ErbB-2.
    Collaboration with:  Y. Yarden
    Monoclonal antibodies (mAbs) to ErbB-1 and ErbB-2 receptors and their role in potential anti-tumor strategy.
    Collaboration with:  B. Schechter, Y. Yarden
    Synergistic effects of combinations of mAb against distinct epitopes on EGFR/ErbB-1 and ErbB-2 receptors: accelerated receptor aggregation, down regulation and inhibition of tumor growth.
    Collaboration with:  B. Schechter, Y. Yarden